profit from every $100 of sales.
$0$100
Dentsply Sirona
$9.16-0.87% today
-16.3% in 1 year
1-year low $8.421-year high $14.68
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Dentsply Sirona sold, what it kept, and what it did with the cash.
Sales went from $3.92 billion in 2022 to $3.68 billion in 2025, with -$598 million of profit last year.
SalesProfit
Dentsply Sirona handed back more cash to shareholders than it generated last year.
$128M
Free cash flow 2025$104M
Bought back its own shares$0
Paid as dividends$128M
Cash vs. debt$326M vs. $2.5B
Dentsply Sirona vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Dentsply Sirona | No profit yet | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.8× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
Compare Dentsply Sirona with Envista
AI analysis
An AI analyst reads Dentsply Sirona's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3,922 | 3,965 | 3,793 | 3,680 | |
| 2,127 | 2,086 | 1,958 | 1,840 | |
| 364 | 289 | 188 | 252 | |
| -662 | 249 | -518 | -46 | |
| -950 | -132 | -910 | -598 | |
| -4.41 | -0.62 | -4.48 | -3.00 | |
| 54.2% | 52.6% | 51.6% | 50.0% | |
| 9.3% | 7.3% | 5.0% | 6.8% | |
| -24.2% | -3.3% | -24.0% | -16.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 7,643 | 7,370 | 5,753 | 5,429 |
| Cash | 365 | 334 | 272 | 326 |
| Total debt | 2,147 | 2,299 | 2,272 | 2,468 |
| Total liabilities | 3,831 | 4,076 | 3,810 | 4,089 |
| 3,811 | 3,293 | 1,942 | 1,339 | |
| 216 | 212 | 203 | 199 | |
| -13.1% | -1.3% | -16.3% | -8.3% | |
| -24.9% | -4.0% | -46.9% | -44.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 517 | 377 | 461 | 235 | |
| 149 | 149 | 180 | 131 | |
| 368 | 228 | 281 | 104 | |
| Dividends paid | 104 | 116 | 126 | 128 |
| 150 | 300 | 250 | 0 | |
| 59 | 46 | 39 | 33 |
Valuation
- –
- 6.4×
- –
- 1.7×
- 0.5×
- 17.6×
- –
- 5.7%
- -32.7%
- 5.7%
Profitability
- 50.0%
- 6.8%
- -16.3%
- -3.5%
- 5.1%
- -10.0%
- -41.2%
- -12.0%
- 5.4%
- 4.3%
Growth
- −2.1%
- –
- −63.0%
- +9.9%
- −2.2%
Financial health
- –
- 1.77
- 44.6%
- 2.4×
- 1.53
- 0.98
- 0.70
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 50%of 946
Bottom 44%of 872
Bottom 12%of 868
Top 17%of 986
What analysts expect
- Average price target
- $13.40
- Range
- $12.00 – $16.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 0.27 | 0.28 | −3.6% |
| Feb 26, 2026 | 0.27 | 0.28 | −3.6% |
| Nov 6, 2025 | 0.37 | 0.45 | −17.8% |
| Aug 7, 2025 | 0.52 | 0.50 | +4.0% |
| May 8, 2025 | 0.43 | 0.29 | +48.3% |
| Feb 27, 2025 | 0.26 | 0.47 | −44.7% |
| Nov 7, 2024 | 0.50 | 0.48 | +4.2% |
| Jul 31, 2024 | 0.49 | 0.50 | −2.0% |
5.7%of the share price, paid each year
On $1,000 invested$57a year at today's yield, before tax
+9.9%2020 to 2025
Raised–not every year
Paid per share, each year
$0.29 in 2015 → $0.64 in 2025
How safe it looks
-20.4% of its profit
Room to growStretchedMore than it earns: 123.1%
News
Does XRAY’s Profit Recovery and Reaffirmed 2026 Outlook Shift the Dentsply Sirona Thesis?Yahoo Finance · Sep 4, 2026The newest story we have is from Sep 4, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
34No pass
Philip Fisher
35No pass
Peter Lynch
12No pass
Joel Greenblatt
0No pass
Charlie Munger
24No pass
Terry Smith
19No pass
Questions about Dentsply Sirona
Is Dentsply Sirona a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Dentsply Sirona AI analysis
What does Dentsply Sirona do?
DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies for professional dental market worldwide. The company operates through two segments, Technologies & Equipment, and Consumables. It is in Medical - Instruments & Supplies.
Does Dentsply Sirona pay a dividend?
Yes. At today's price the dividend is 5.7% a year. In 2025 it paid out $128 million in dividends.
Is Dentsply Sirona stock halal?
No. Dentsply Sirona does not pass our halal screen: its debt is 135% of its market value, at or above the 33% limit. How we check
How has Dentsply Sirona stock done over the past year?
Down 16.3% over the past twelve months, to $9.16. It traded between $8.42 and $14.68 and is 37.6% below its high.
Who are Dentsply Sirona's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with Dentsply Sirona's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.